# Kunlun Capital

> Kunlun Capital is a VC fund in Singapore backing Biotechnology and Health Care. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Singapore, Singapore
- Total investments: 16
- Last investment: May 2022
- Lead investor: 19%
- Last updated: Aug 2026
- Website: https://www.kunluncapital.com/

Kunlun Capital is a value-oriented and fundamentally driven family office. We do not manage external funds.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $20M–$31M |
| Series A | $5.4M–$40M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 56% |
| Health Care | 4 | 25% |
| Medical | 3 | 19% |
| Genetics | 3 | 19% |
| Biopharma | 2 | 13% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 25% |
| Seed | 3 | 19% |
| Series B | 2 | 13% |
| Angel | 1 | 6% |
| Series C | 1 | 6% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| HuidaGene Therapeutics | Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases. |  | Series C | May 12, 2022 |  |
| Ningbo Shanshan | Ningbo Shanshan engaged in the research and development, manufacture and distribution of lithium battery materials. | $477M | Post-IPO Equity | Apr 19, 2022 |  |
| CellOrigin Biotech | CellOrigin Biotech is a company committed to iPSC-derived innate immune cell therapeutics. | $15.7M | Venture - Series Unknown | Mar 29, 2022 |  |
| Nutshell Therapeutics | Inventing small molecule in the realm of drug discovery fostered by protein dynamics. | $40M | Series A | Mar 14, 2022 |  |
| UniXell | UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders. | $31.4M | Seed | Mar 14, 2022 |  |
| YUSUR Technology | Zhongke Digital is a Chinese company that specializes in the development of dedicated computing architectures for finance, artificial intelligence, and blockchain. The company is based in Beijing. China. |  | Series A | Dec 21, 2021 |  |
| YUSUR Technology | Zhongke Digital is a Chinese company that specializes in the development of dedicated computing architectures for finance, artificial intelligence, and blockchain. The company is based in Beijing. China. |  | Series A | Dec 21, 2021 |  |
| Circular Code Biology | Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform. | $20M | Seed | Dec 16, 2021 |  |
| CirCode | CirCode utilizes mRNA biotechnology to develop new biomedicine and drugs. | $20M | Seed | Dec 16, 2021 |  |
| Danwang Medical | Danwang Medical is a research organization focusing on regenerative medicine and organoid technology. | $18.6M | Series A | Oct 14, 2021 |  |

10 of 16 investments shown.

## Co-investors
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 3 deals together
- [Sherpa Healthcare Partners](https://shizune.co/investors/profile/sherpa-venture-capital) — VC Fund, 3 deals together
- [Alwin Capital](https://shizune.co/investors/profile/alwin-capital) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [Cowin Capital](https://shizune.co/investors/profile/cowin-capital) — VC Fund, 2 deals together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)
- [Web3 Investors in China](https://shizune.co/investors/web3-investors-china)
- [Web3 VC Funds in China](https://shizune.co/investors/web3-vc-funds-china)
- [Finance Investors in China](https://shizune.co/investors/finance-investors-china)
- [Finance VC Funds in China](https://shizune.co/investors/finance-vc-funds-china)

## FAQ

### What does Kunlun Capital invest in?

Kunlun Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Kunlun Capital's check size?

Kunlun Capital typically joins rounds of $20M–$31M at Seed and $5.4M–$40M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kunlun Capital participates in.

### When did Kunlun Capital last invest?

The most recent investment recorded for Kunlun Capital closed in May 2022. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co